Oculis Holding AG (OCS) Intangibles (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Intangibles of $17.0 million for Q1 2026, up 14.81% year-over-year from $14.8 million in Q1 2025, and up 2.06% quarter-over-quarter from $16.6 million in Q4 2025.
Oculis Holding AG (OCS) Intangibles (2021 - 2026) Analysis & Trends
Oculis Holding AG's Intangibles history runs 6 years deep, the most recent figure standing at $17.0 million for Q1 2026.
- In Q1 2026, Intangibles rose 14.81% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at $17.0 million (up 14.81% YoY), while the FY2025 annual figure was $16.0 million, up 6.11% from the prior year.
- Intangibles for Q1 2026 stood at $17.0 million, up from $16.6 million in the prior quarter.
- The five-year high for Intangibles was $17.0 million in Q1 2026, with the low at $12.7 million in Q4 2022.
- The 5-year median for Intangibles is $14.1 million (2024), against an average of $14.7 million.
- The sharpest annual moves came in 2022 and 2024: Intangibles jumped 33.92% in 2022, then retreated 0.57% in 2024.
- Oculis Holding AG's Intangibles stood at $12.7 million in 2022, then rose by 8.61% to $13.8 million in 2023, then gained by 10.27% to $15.2 million in 2024, then grew by 9.61% to $16.6 million in 2025, then rose by 2.06% to $17.0 million in 2026.
- Business Quant data shows OCS's Intangibles at $17.0 million in Q1 2026, $16.6 million in Q4 2025, and $16.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | 16.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.82 Mn |
| Mar 31, 2026 | 16.97 Mn |
| Dec 31, 2025 | 16.63 Mn |
| Sep 30, 2025 | 16.62 Mn |
| Jun 30, 2025 | 16.06 Mn |
| Mar 31, 2025 | 14.78 Mn |
| Dec 31, 2024 | 15.17 Mn |
| Sep 30, 2024 | 14.09 Mn |
| Jun 30, 2024 | 13.50 Mn |
| Mar 31, 2024 | 13.98 Mn |
| Dec 31, 2023 | 13.76 Mn |
| Sep 30, 2023 | 13.82 Mn |
| Jun 30, 2023 | 13.58 Mn |
| Dec 31, 2022 | 12.67 Mn |
| Dec 31, 2021 | 9.46 Mn |